Reni Benjamin
Stock Analyst at JMP Securities
(1.39)
# 3,279
Out of 4,711 analysts
156
Total ratings
36.17%
Success rate
-12.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $32 → $26 | $14.68 | +77.11% | 12 | Dec 18, 2024 | |
| STRO Sutro Biopharma | Reiterates: Market Outperform | $17 | $1.88 | +804.26% | 9 | Dec 11, 2024 | |
| PRLD Prelude Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.30 | +207.69% | 3 | Dec 11, 2024 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $6 | $1.03 | +482.52% | 6 | Dec 11, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $90.14 | +38.67% | 18 | Dec 9, 2024 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $32 | $9.01 | +255.16% | 8 | Nov 19, 2024 | |
| SANA Sana Biotechnology | Downgrades: Market Perform | n/a | $1.65 | - | 4 | Nov 5, 2024 | |
| TIL Instil Bio | Initiates: Market Perform | n/a | $20.61 | - | 1 | Nov 4, 2024 | |
| SMMT Summit Therapeutics | Initiates: Market Outperform | $32 | $17.87 | +79.07% | 1 | Nov 4, 2024 | |
| BGNE BeiGene | Initiates: Market Outperform | $288 | $176.50 | +63.17% | 1 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $68.84 | - | 25 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.69 | +622.23% | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $2 | $1.01 | +98.02% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $14.60 | - | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $12 | $1.59 | +654.72% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $23 | $7.38 | +211.65% | 10 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.87 | - | 6 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.91 | - | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $1.53 | +161.44% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $4.74 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $5.75 | +195.65% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.59 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.91 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $7.62 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $3.18 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.60 | +2,545.07% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $17.40 | -42.53% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $32.20 | -62.73% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.64 | - | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.36 | - | 2 | Nov 10, 2017 |
Bicycle Therapeutics
Dec 18, 2024
Maintains: Market Outperform
Price Target: $32 → $26
Current: $14.68
Upside: +77.11%
Sutro Biopharma
Dec 11, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $1.88
Upside: +804.26%
Prelude Therapeutics
Dec 11, 2024
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.30
Upside: +207.69%
LAVA Therapeutics
Dec 11, 2024
Downgrades: Market Perform
Price Target: $6
Current: $1.03
Upside: +482.52%
Blueprint Medicines
Dec 9, 2024
Reiterates: Market Outperform
Price Target: $125
Current: $90.14
Upside: +38.67%
Kura Oncology
Nov 19, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $9.01
Upside: +255.16%
Sana Biotechnology
Nov 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.65
Upside: -
Instil Bio
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $20.61
Upside: -
Summit Therapeutics
Nov 4, 2024
Initiates: Market Outperform
Price Target: $32
Current: $17.87
Upside: +79.07%
BeiGene
Sep 18, 2024
Initiates: Market Outperform
Price Target: $288
Current: $176.50
Upside: +63.17%
Sep 17, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $68.84
Upside: -
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.69
Upside: +622.23%
Jul 26, 2024
Maintains: Market Outperform
Price Target: $15 → $2
Current: $1.01
Upside: +98.02%
Jul 23, 2024
Initiates: Market Perform
Price Target: n/a
Current: $14.60
Upside: -
Jun 26, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $1.59
Upside: +654.72%
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $7.38
Upside: +211.65%
Jan 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.87
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.91
Upside: -
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.53
Upside: +161.44%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.74
Upside: -
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $5.75
Upside: +195.65%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.59
Upside: -
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.91
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $7.62
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $3.18
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.60
Upside: +2,545.07%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $17.40
Upside: -42.53%
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $32.20
Upside: -62.73%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $10.64
Upside: -
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $0.36
Upside: -